Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.

Blood - 15 Mar 2004

Zimmerman Sherri A, Schultz William H, Davis Jacqueline S, Pickens Chrisley V, Mortier Nicole A, Howard Thad A, Ware Russell E

Abstract excerpt

Hydroxyurea improves hematologic parameters for children with sickle cell disease (SCD), but its long-term efficacy at maximum tolerated dose (MTD) has not been determined. Between 1995 and 2002, hydroxyurea therapy was initiated for 122 pediatric patients with SCD including 106 with homozygous sickle cell anemia (HbSS), 7 with sickle hemoglobin C (HbSC), 7 with sickle/beta-thalassemia (HbS/ beta-thalassemia [6...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to Fetal Hemoglobin

Share to Hydroxyurea

Share to Infant

Share to Leukocyte Count

Share to Treatment Outcome

Source

Identifiers

PMID: 14630791
DOI: 10.1182/blood-2003-07-2475

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease.PMID 14630791Read ↗

Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension studySemantic proximity Read ↗

A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapySemantic proximity Read ↗

Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia.Semantic proximity Read ↗

Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseSemantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

Emerging science of hydroxyurea therapy for pediatric sickle cell disease.Semantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.Semantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia.Semantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Low and fixed dose of hydroxyurea is effective and safe in patients with HbSβ(+) thalassemia with IVS1-5(G→C) mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.